Anita Szőke

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir, Jennifer R. Brown, Susan O’Brien et al. · American Journal of Hematology · 2019 · 473 citations · Full text

Medicine, Oncology, Pharmacology +14

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 380 citations · Full text

Medicine, Hematology, Pharmacology +13

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 314 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 

Paul M. Barr, Carolyn Owen, Tadeusz Robak et al. · Blood Advances · 2022 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Stroke in essential thrombocythemia

Éva Pósfai, Imelda Marton, Anita Szőke et al. · Journal of the Neurological Sciences · 2013 · 44 citations

Medicine, Hematology, Neurology +10